



This is a convenience translation of the German original. In case of discrepancy between the English and German versions, the German version shall prevail.

Ordinance of the Federal Office for Safety in Health Care (*Bundesamt für Sicherheit im Gesundheitswesen, BASG*) On the Schedule of Fees Pursuant to the Austrian Health and Food Safety Act (*Gesundheits- und Ernährungssicherheitsgesetz, GESG*)

Based on Article 6a paragraph 6 of the GESG, Federal Law Gazette (*Bundesgesetzblatt, BGBl.*) I No. 63/2002, last amended by Federal Law Gazette I No. 139/2024 , it is herewith ordained as follows:

Article 1. (1) The fees for services pursuant to Article 6a paragraph 6 of the Austrian Health and Food Safety Act (GESG) are set forth in the Annex to this Ordinance.

(2) All fees, with the exception of those referred to in Section VII of the Annex, shall be payable upon invoicing within the specified time following assessment of the formal requirements or receipt of documentation. The fees specified in Section VII of the Annex as well as fees for ex officio action shall be payable upon issuance of the administrative decision or after invoicing.

(3) For applications rejected or withdrawn before the assessment of formal requirements has been completed, the amount payable shall be 10 percent of the applicable fee. For applications rejected or withdrawn after this time, the full fee shall be payable.

(4) The fees for official actions as specified in Section X of the Annex shall be payable by the party that brings the product to market.

Article 2. (1) For the purposes of this Ordinance, "academic clinical study" shall be understood to mean the clinical trial of a medicinal product, the clinical investigation of a medical device, or the performance evaluation of an in-vitro diagnostic in which the investigator, a university or technical college, or a public hospital provider takes on the role of sponsor.

(2) If a clinical investigation of a medical device is submitted at the same time, in the same context, and by the same sponsor as the clinical trial of a medicinal product, the amount payable shall be equivalent to the full fee as specified in Section XII.1 or XII.2 of the Annex plus 35 percent of the applicable fee as specified in Section XI.1.a, XI.1.b, or XI.2 of the Annex.

(3) For academic clinical studies, the fees as specified in Section VII.6 of the Annex shall be waived.

(4) For fees payable for clinical trials in accordance with Regulation (EU) 536/2014 as specified in Section XI.2 of the Annex, the following categories have been defined:

- Category A: The investigational medicinal product (except placebos) is authorised in the European Economic Area (EEA), may have been modified, and
- is used in accordance with the terms of its marketing authorisation or in a manner considered evidence-based in Austria, and
- the study-related measures pose only a minimal additional risk to or impose only a minimal additional burden on the safety of the study participants compared to normal clinical practice.



- Category B: The investigational medicinal product (except placebos) is authorised in the EEA, may have been modified, and
 - 1) is not used in accordance with its marketing authorisation or in a manner considered evidence-based in Austria, and/or
 - 2) the study-related measures pose a more than minimal additional risk to or impose a more than minimal additional burden on the safety of the study participants compared to normal clinical practice.
- Category C: The investigational or auxiliary medicinal product is not authorised.

(5) For trials with a medicinal product authorised for use in patients in the EEA that investigate said product in healthy volunteers without a medical indication but otherwise comply with the terms of the marketing authorisation, a fee in accordance with category A shall be charged.

(6) The subsequent addition of a concerned Member State in accordance with Article 14 of Regulation (EU) 536/2014 where Austria is the additional Member State concerned shall be charged in accordance with the fees payable for an initial application with Austria as concerned Member State.

(7) The subsequent addition of a concerned Member State in accordance with Article 14 of Regulation (EU) 536/2014 where Austria is the reporting Member State shall be charged in accordance with the fees payable for a modification requiring authorisation.

(8) In the case of a split submission pursuant to Article 11 of Regulation (EU) 536/2014, the fees for the assessment of the global aspects (Part I) by BASG and the competent ethics committee and the fees for the assessment of the national aspects (Part II) by the competent ethics committee shall be charged separately. In addition, an extra service fee shall be charged by BASG as specified in Section XI.2.e. of the Annex.

(9) Depending on the types of documents modified as part of an application for the assessment of a substantial modification in accordance with Chapter III of Regulation (EU) 536/2014, fees may arise for the assessment by BASG, the competent ethics committee, or both. In case of a substantial modification that is subject to assessment by the competent ethics committee only (Part II), an additional service fee for tasks performed by BASG as specified in Section XI.3.e of the Annex shall apply.

Article 3. (1) For the purpose of this Schedule of Fees, a marketing authorisation of a known active substance is one where the proprietary medicinal product contains only such active substances as are contained in proprietary medicinal products

1. which, at the time of application, are authorised in one of the contracting parties to the Agreement on the EEA and
2. whose marketing authorisation relates to an application similar to that under review.

(2) For the purpose of this Schedule of Fees, a marketing authorisation of a new substance is one where not all of the conditions set forth in paragraph 1 are met.

(3) An extension of an existing marketing authorisation within the meaning of Regulation (EC) No 1234/2008 or a corresponding modification of an existing market authorisation in accordance with Article 62 Regulation (EU) 2019/6 that results in a new and separate authorisation number shall be charged as specified in Section I of the Annex.



Article 4. For applications for marketing authorisation of two or more proprietary medicinal products of the same product family in accordance with Sections I.1, I.2, or I.3., items a, b, c, and d, or in accordance with Section I.4 of the Annex

1. which are submitted simultaneously by the same applicant,
2. whose active substances are of the same kind, and
3. whose medical use has similar evaluation requirements,

the full fee shall be charged for the first of these applications, and 50 percent of that fee shall be charged for any additional application.

Article 4a. (1) If, in a mutual recognition or decentralised procedure with Austria as reference Member State (RMS), additional duplicate dossiers (i.e., dossiers which, with the exception of the name of the proprietary medicinal product, are identical) are submitted simultaneously or during an ongoing authorisation procedure, the fee payable for such duplicate dossiers and related subsequent applications in accordance with Section I.1.a, I.2.a, and IX.1.a of the Annex shall be reduced by 50 percent. This reduction applies only if the duplicate dossiers are submitted by the same applicant or marketing authorisation holder.

(2) If, at the time of notification of the intended distribution of proprietary medicinal products through distance selling pursuant to Article 59a of the Austrian Medicinal Products Act (*Arzneimittelgesetz*, AMG) or Article 50 of the Austrian Veterinary Medicinal Products Act (mail-order pharmacy), an identical notification regarding a website with identical content and purpose is submitted to BASG, the fee payable for such notification in accordance with Section VII.10 of the Annex shall be reduced by 50 percent.

Article 5. For Periodic Safety Update Reports (PSURs) (as defined in Article 2b paragraph 9 AMG) on two or more medicinal products which are

1. submitted simultaneously by the same marketing authorization holder,
2. deal with (an) identical active substance(s), and
3. whose medical use has similar evaluation requirements,

the full fee shall be payable for the most expensive of these applications, while any additional applications shall be charged at 50 percent of the applicable fee.

Article 6. (1) For authorisations and other activities pertaining to veterinary medicinal products, a fee amounting to 60 percent of the fee as specified in Sections I, IV, V.6, VI, VII, and VIII (except Sections VIII.6 and 7) of the Annex and in Article 8 paragraph 4 will be charged.

(2) For veterinary medicinal products, a fee amounting to 55 percent of that specified in Section II of the Annex will be charged.

(3) For marketing authorisations for limited markets and in exceptional circumstances pursuant to Articles 23 and 25 of Regulation (EU) 2019/6, respectively, a fee amounting to 45 percent of that specified in Section I of the Annex will be charged.



Article 7. (1) An “inspection half-day” is defined as a period of a maximum of 4 hours, or any fraction thereof, spent by an inspector working on site or in direct relation with an inspection.

(2) Travel expenses incurred in relation with an inspection outside of Austria in accordance with Section VII of the Annex are not included in the fees listed and shall be charged separately; for national inspections, a flat rate for travel expenses of EUR 256.00 shall be charged.

Article 8. (1) In case cash expenditures pursuant to Article 76 of the Austrian General Administrative Procedures Act (*Verwaltungsverfahrensgesetz*) 1991, Federal Law Gazette I No. 51/1991 as amended, are incurred in connection with either a procedure or other activities for which fees are payable in accordance with this Fees Ordinance, these cash expenditures shall be considered an integral part of the fee as stipulated by the Schedule of Fees, unless these cash expenditures exceed the fee payable. In the latter case, a fee of 20 percent of the fee specified in the Schedule of Fees plus the sum total of cash expenditures incurred shall be payable. If cash expenditures arise in relation to a procedure otherwise considered paid and settled by an annual flat fee as specified in Section II, such expenditures shall be settled in full by the applicant.

(2) Other services not listed in the Annex or additional services shall be charged, after consultation with the applicant, at an hourly rate of EUR 196.00.

(3) The annual flat fee as specified in Section II of the Annex shall be payable by the marketing authorisation holder, registration holder, or holder of a license pursuant to Article 7a AMG. The annual flat fee shall be invoiced, on a pro rata basis, at the end of each quarter for all medicinal products authorised, registered, approved, or licensed as per the last working day of the respective quarter. The annual flat fee as specified in Section II of the Annex is also payable for authorisations or registrations whose suspension has been ordered by BASG.

(3a) The annual flat fee as specified in Section III.2 of the Annex shall be payable by the holder of a parallel import license. This fee shall be invoiced, on a pro rata basis, at the end of each quarter for all (proprietary) medicinal products licensed for parallel import as per the last working day of the respective quarter.

(3b) The annual flat fee as specified in Section VII.11 of the Annex shall be invoiced to the person entitled to distance selling pursuant to Article 59a paragraph 2 AMG or Article 50 TAMG by May 31 of each subsequent year, with the invoice payable within the period specified therein.

(4) For applications, notifications, or other documentation not submitted electronically as required by the BASG Ordinance on the Electronic Submission of Applications and Notifications (Electronic Submission Ordinance, EEVO) of 2011 as amended, the prescribed fee increases by 5 percent.

Article 9. This Ordinance shall enter into force on 1. January 2025.



1 Explanatory note: On 15 January 2006, the Ordinance of the Federal Office for Safety in Health Care (BASG) On the Schedule of Fees Pursuant to the Austrian Health and Food Safety Act (GESG) (published on 18 January 2006 in the Official Gazette of the Republic of Austria's official newspaper for public announcements, i.e., *Amtsblatt zur Wiener Zeitung*) entered into force.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 02/2006 (*BASG VO Nr. 02/2006*) entered into force on 15 January 2007.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 01/2008 (*BASG VO Nr. 01/2008*) entered into force on 03 November 2008.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 01/2009 (*BASG VO Nr. 01/2009*) entered into force on 26 March 2009.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 02/2009 (*BASG VO Nr. 02/2009*) entered into force on 01 January 2010.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 01/2011 (*BASG VO Nr. 01/2011*) entered into force on 28 November 2011.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 01/2012 (*BASG VO Nr. 01/2012*) entered into force on 08 November 2012.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 01/2013 (*BASG VO Nr. 01/2013*) entered into force on 24 January 2013.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 02/2013 (*BASG VO Nr. 02/2013*) entered into force on 04 August 2013.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 03/2013 (*BASG VO Nr. 03/2013*) entered into force on 02 January 2014.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 01/2015 (*BASG VO Nr. 01/2015*) entered into force on 04 May 2015.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 02/2015 (*BASG VO Nr. 02/2015*) entered into force on 01 January 2016.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 01/2016 (*BASG VO Nr. 01/2016*) entered into force on 31 January 2016.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 02/2016 (*BASG VO Nr. 02/2016*) entered into force on 09 May 2016.



The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 03/2016 (*BASG VO Nr. 03/2016*) entered into force on 15 July 2016.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 04/2016 (*BASG VO Nr. 04/2016*) entered into force on 01 January 2017.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 01/2017 (*BASG VO Nr. 01/2017*) entered into force on 01 June 2017.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 02/2017 (*BASG VO Nr. 02/2017*) entered into force on 01 January 2018.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 02/2018 (*BASG VO Nr. 02/2018*) entered into force on 01 September 2018.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 03/2018 (*BASG VO Nr. 03/2018*) entered into force on 01 January 2019.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 01/2019 (*BASG VO Nr. 01/2019*) entered into force on 01 January 2020.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 02/2020 (*BASG VO Nr. 02/2020*) entered into force on 01 July 2020.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 03/2020 (*BASG VO Nr. 03/2020*) entered into force on 01 January 2021.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 01/2021 (*BASG VO Nr. 01/2021*) entered into force on 01 August 2021.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 02/2021 (*BASG VO Nr. 02/2021*) entered into force on 01 January 2022.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 03/2021 (*BASG VO Nr. 03/2021*) entered into force on 28 January 2022.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 01/2022 (*BASG VO Nr. 01/2022*) entered into force on 15 August 2022.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 02/2022 (*BASG VO Nr. 02/2022*) entered into force on 01 January 2023.

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 01/2023 (*BASG VO Nr. 01/2023*) entered into force on 01 January 2024.



Bundesamt für
Sicherheit im
Gesundheitswesen
BASG

The amendment to the Fees Ordinance as enacted by Federal Office for Safety in Health Care Ordinance No. 01/2023 (*BASG VO Nr. 02/2024*) entered into force on 01 June 2024.

For the changes enacted with these amendments, see the respective ordinances as published by the Federal Office for Safety in Health Care (BASG) under "Official Announcements."

Any fees payable shall be based on the Fees Ordinance in force on the day an application is/was submitted.



Annex

Section	Service provided	EURO
I.	Marketing authorisation for proprietary medicinal products	
I.1	Obtaining marketing authorisation in the mutual recognition procedure pursuant to Article 18a (1) of the Austrian Medicinal Products Act (<i>Arzneimittelgesetz, AMG</i>) or Article 52 of Regulation (EU) 2019/6	
I.1.a	As reference Member State (RMS) Update	
I.1.a.1	For a proprietary medicinal product containing a new active substance	51.814
I.1.a.2	For a proprietary medicinal product containing a known active substance	39.553
I.1.a.3	Repeat-use procedure or subsequent recognition procedure pursuant to Article 53 of Regulation (EU) 2019/6	7.911
I.1.a.4	Day-0 repeat-use procedure (purely administrative repeat-use marketing authorisation procedure) or subsequent recognition procedure	976
I.1.b	As concerned Member State (CMS)	8.964
I.2	Obtaining marketing authorisation in the decentralised procedure pursuant to Article 18a AMG or Article 49 of Regulation (EU) 2019/6	
I.2.a	As reference Member State (RMS)	
I.2.a.1	For a proprietary medicinal product containing a new active substance	65.920
I.2.a.2	For a proprietary medicinal product containing a known active substance	48.780
I.2.b	As concerned Member State (CMS)	
I.2.b.1	For a proprietary medicinal product containing a new active substance	11.287
I.2.b.2	For a proprietary medicinal product containing a known active substance	8.964
I.3	Obtaining marketing authorisation in the national procedure	
I.3.a	Marketing authorisation pursuant to Article 9a AMG or Article 8 TAMG in conjunction with Article 8 of Regulation (EU) 2019/6	
I.3.a.1	For a proprietary medicinal product containing a new active substance	14.108



I.3.a.2	For a proprietary medicinal product containing a known active substance	9.228
I.3.b	Marketing authorisation pursuant to Article 10a AMG (application based on bibliographic data) or Article 22 of Regulation (EU) 2019/6	8.921
I.3.c	Marketing authorisation pursuant to Article 10 AMG (application for a generic medicinal product) or Article 18 of Regulation (EU) 2019/6	8.921
I.3.d	Marketing authorisation pursuant to Article 10b AMG (application for a new combination) or Article 20 of Regulation (EU) 2019/6	9.228
I.3.e	Special marketing authorisation situations with simplified requirements	
I.3.e.1	Marketing authorisation for active substances or manufacturing processes pursuant to Article 7a AMG	2.639
I.3.e.2	Marketing authorisation pursuant to Article 9b AMG or Article 5 of Regulation (EU) 2019/6	
I.3.e.2.a	For a homoeopathic single remedy	1.319
I.3.e.2.b	For a homoeopathic complex remedy	4.615
I.3.e.3	Pharmacopoeial monograph pursuant to Article 9c or 9d AMG	1.582
I.4	Fees for Liechtenstein pursuant to the Agreement between the Austrian Federal Government and the Government of the Principality of Liechtenstein (Federal Law Gazette III No. 126/2010)	
I.4.a	Austria acts as CMS for Liechtenstein in an application simultaneously submitted in Austria pursuant to Section I.1 or I.2 (DCP, MRP)	1.782
I.4.b	Austria acts as CMS for Liechtenstein in an application subsequently submitted in Austria pursuant to Section I.1 or I.2 (DCP, MRP)	4.482
II.	Annual flat fee per (proprietary) medicinal product	
	Marketing authorisations	
II.1	For authorised proprietary medicinal products with Austria as RMS	3.824
II.2	For authorised proprietary medicinal products with Austria as CMS	1.979
II.3	For purely nationally authorised proprietary medicinal products	1.648
II.4	For proprietary medicinal products authorised pursuant to Article 9b AMG or Article 5 of Regulation (EU) 2019/6	397



II.5	For proprietary medicinal products authorised pursuant to Article 9c AMG	397
II.6	For proprietary medicinal products authorised pursuant to Article 9b AMG with Austria as RMS	790
II.7	For proprietary medicinal products authorised pursuant to Article 9b AMG with Austria as CMS	397
	Registrations	
II.8	For proprietary medicinal products pursuant to Article 7a AMG	397
II.9	For registered proprietary medicinal products pursuant to Article 11 AMG or Article 86 of Regulation (EU) 2019/6	34
II.10	For registered proprietary medicinal products pursuant to Article 11a AMG	34
II.11	For registered proprietary medicinal products pursuant to Article 12 AMG	397
II.12	For registered proprietary medicinal products pursuant to Article 11 AMG with Austria as RMS	790
II.13	For registered proprietary medicinal products pursuant to Article 11 AMG with Austria as CMS	397
II.14	For registered proprietary medicinal products pursuant to Article 12 AMG with Austria as RMS	790
II.15	For registered proprietary medicinal products pursuant to Article 12 AMG with Austria as CMS	397
III.	Parallel import license	
III.1	Application for a parallel import license	1.319
III.2	Annual flat fee per proprietary medicinal product licensed for parallel import	660
IV.	Registrations/notifications pursuant to AMG	
IV.1	Registration pursuant to Article 11 AMG or Article 86 of Regulation (EU) 2019/6	
IV.1.a	For a homeopathic single remedy	527



IV.1.b	For a homeopathic complex remedy	1.844
IV.2	Registration of traditional herbal medicinal products	
IV.2.a	Pursuant to Article 12 AMG	3.692
IV.2.b	Pursuant to Article 12 AMG in accordance with a pharmacopoeial monograph	1.582
IV.3	Low-quantity confirmation for radioactive medicinal products pursuant to Article 7 paragraph 11 AMG	527
IV.4	Registration of homoeopathic proprietary medicinal products in the decentralized or mutual recognition procedure pursuant to Article 18a AMG with Austria	
IV.4.a	As reference Member State (RMS)	5.273
IV.4.b	As concerned Member State (CMS)	1.054
IV.5	Registration of pharmacy-produced proprietary medicinal products pursuant to Article 11a AMG	1.313
IV.6	Registration of traditional herbal medicinal products in the decentralized or mutual recognition procedure pursuant to Article 18a AMG with Austria	
IV.6.a	As reference Member State (RMS)	
IV.6.a.1	For products complying with a European herbal monograph pursuant to Article 16h paragraph 3 of Directive 2001/83/EC	7.348
IV.6.a.2	For products not complying with a European herbal monograph pursuant to Article 16h paragraph 3 of Directive 2001/83/EC	22.038
IV.6.b	As concerned Member State (CMS)	3.692
V.	Miscellaneous	
V.1	Decision transcript	160
V.2	Determination application pursuant to Article 1 paragraph 3b AMG or Article 2 paragraph 5 TAMG	2.905
V.3	National scientific advice	
V.3.a	For new active substances (in the EEA) and biosimilars	11.602



V.3.b	For known active substances (in the EEA)	7.251
V.4	Laboratory analyses for other authorities, per sample	
V.4.a	Qualitative and quantitative analysis	655
V.4.b	Qualitative analysis	395
V.4.c	For the qualitative and quantitative analysis of qualitatively identical samples submitted simultaneously by the same applicant, the full fee as specified in Section V.4.a shall be charged for the first sample, while each additional sample shall be charged at	395
V.4.d	For the qualitative analysis of qualitatively identical samples submitted simultaneously by the same applicant, the full fee as specified in Section V.4.b shall be charged for the first sample, while each additional sample shall be charged at	263
V.4.e	Sampling for laboratory analyses for other authorities	256
V.5	Fees for the processing of quality defects pursuant to Article 75q AMG or Article 42 TAMG or recalls (classification pursuant to the "Guidance and Procedures for Competent Authorities: Crisis Management regarding Defects of Centrally Authorised Products, Classification of Batch Recalls for Quality Defects") for authorised, registered, approved, or licensed medicinal products	
V.5.a	Quality defects pursuant to Article 75q AMG or Article 42 TAMG	1.979
V.5.b	Class I defects	1.979
V.5.c	Class II defects	1.319
V.5.d	Class III defects	1.054
V.6	Change in RMS (Austria takes on role as RMS)	5.933
V.7	Notifications in relation to the handling of or trade with addictive substances within the meaning of Article 6 paragraph 1 clause 1 of the Austrian Narcotic Substances Act (<i>Suchtmittelgesetz, SMG</i>) per business, by number of reported active substances	
V.7.a	0 active substances (handling fee for nil notification)	194
V.7.b	1 to 5 active substances	655
V.7.c	6 to 20 active substances	1.313



V.7.d	More than 20 active substances	2.622
VI.	Batch testing pursuant to Article 26 AMG or Article 23 TAMG	
VI.1	Batch release notification	132
VI.2	Plasma pool testing	264
VI.3	Batch testing of plasma products	
VI.3.a	Human albumin	1.755
VI.3.b	Immunoglobulins	1.755
VI.3.c	Coagulation factors, tissue sealants, plasma	2.639
VI.4	Batch testing of vaccines without animal testing	1.755
VI.5	Batch testing of vaccines with animal testing	6.594
VI.6	Batch testing of proprietary medicinal products containing a blood product as excipient	790
VII.	Site inspection, operating license, and registration of a sampling site	
VII.1	Operating license pursuant to Articles 63 and 63a AMG, Article 30 paragraph 1 TAMG, Article 88 of Regulation (EU) 2019/6, Article 14 paragraph 1 of the Austrian Blood Safety Act (<i>Blutsicherheitsgesetz</i> , BSG) or Article 22 of the Austrian Tissue Safety Act (<i>Gewebesicherheitsgesetz</i> , GSG)	3.955
VII.2	Change of operating license pursuant to Article 65 AMG, Article 31 paragraph 1 TAMG, Article 92 of Regulation (EU) 2019/6, Article 14 paragraph 3 BSG or Article 22 paragraph 2 GSG	2.639
VII.3	Site inspection pursuant to Articles 59a and 67 AMG, Article 36 paragraph 1 TAMG, Article 123 of Regulation (EU) 2019/6, Article 68 of the Austrian Medical Devices Act (<i>Medizinproduktegesetz</i> , MPG) as amended by Federal Law Gazette I No. 46/2021, Article 38 MPG 2021 as amended, Article 93 Regulation (EU) 2017/745, Article 88 Regulation (EU) 2017/746, Article 26 GSG, Article 18 BSG, Article 6a paragraph 1 clauses 7 and 8 and paragraph 1b GESG, as well laboratory inspections as a precondition for issuing Good Laboratory Practice (GLP) certificates	



VII.3.a	Per inspection half-day or any fraction thereof, in Austria	1.313
VII.3.b	Per inspection half-day or any fraction thereof, outside of Austria	1.443
VII.4	Registration of a notifiable expert in accordance with AMG, TAMG, GSG, or BSG or one of its ordinances (qualified person, information officer, etc.) according to time spent according to Article 8 paragraph 2	
VII.5	Inspection of a pharmacovigilance recording system pursuant to Article 75f AMG or Article 39 TAMG, per inspection half-day or any fraction thereof	1.252
VII.6	Inspections of a clinical trial pursuant to Article 47 AMG or Article 41 MPG as amended by Federal Law Gazette I No. 46/2021 or Article 31 MPG 2021 as amended, per inspection half-day	1.648
VII.7	Inspection of a design qualification, per hour or any fraction thereof	197
VII.8	Registration/certification of a sampling site pursuant to Article 19 GSG	1.979
VII.9	Operative changes at a sampling site pursuant to Article 19 paragraph 2 GSG	990
VII.10	Notification of intended activities pursuant to Article 59a AMG or Article 50 TAMG (mail-order pharmacy)	2.175
VII.11	Annual flat fee for activities pursuant to Article 59a AMG or Article 50 TAMG (mail-order pharmacy)	461
VII.12	Increase in fees as specified in Sections VII.1, VII.2, VII.8, and VII.9 for each additional inspection half-day required	1.313
VIII.	Import of pharmaceutical and medicinal products	
VIII.1	Issuance of import certificate for bulk products, per pharmaceutical product	329
VIII.2	Issuance of import certificate for pharmaceutical products used in a clinical trial	329
VIII.3	Issuance of import certificate for pharmaceutical products intended for re-export, per pharmaceutical product	329
VIII.4	Issuance of import certificate for pharmaceutical products pursuant to Article 5 paragraph 1 clause 2 of the Austrian Pharmaceutical Products Import Act (<i>Arzneiwareneinfuhrgesetz, AWEG</i>) 2010 (scientific purpose without use in humans or animals)	65
VIII.5	Issuance of marketability certificate pursuant to Article 12 AWEG 2010 (except for beneficiaries pursuant to Article 2 of the Austrian Fees Act,	329



	<i>Gebührengesetz, 1957)</i>	
VIII.6	Issuance of import certificate for immunologic veterinary medicinal products, subheading 3002 30 (from non-EEA country)	329
VIII.7	Notification pursuant to Article 8 AWEK 2010 (immunologic veterinary medicinal products, subheading 3002 30), if importation of the product concerned is subject to approval pursuant to Article 12 of the Austrian Animal Diseases Act (<i>Tierseuchengesetz</i>)	167
VIII.8	Issuance of import certificate for products derived from natural health-promoting resources pursuant to Article 18 AWEK 2010	329
VIII.9	Issuance of import certificate for pharmaceutical products intended for destruction	329
VIII.10	Notification on the shipment of blood products pursuant to Article 14 paragraph 1 AWEK	328
IX.	Periodic Safety Update Reports (PSURs)	
IX.1	Submission of a PSUR for a proprietary medicinal product for human use	
IX.1.a	Authorised in a procedure with Austria as RMS	4.746
IX.1.b	Authorised in a procedure with Austria as CMS or in a purely national procedure	660
IX.1.c	Authorised pursuant to Article 9b AMG or registered pursuant to Article 11a AMG	132
X.	Conformity assessment, classification, and differentiation of medical devices from other products	
X.1	Fees pursuant to Article 22 paragraph 3 MPG as amended by Federal Law Gazette I No. 46/2021 based on the amount of time spent in accordance with Article 8 paragraph 2 of this Ordinance, plus any expenses for external expert assessments	
X.2	Classification procedure pursuant to Article 26 MPG as amended by Federal Law Gazette I No. 46/2021, pursuant to Article 51 (2) of Regulation (EU) 2017/745, or pursuant to Article 47 (2) of Regulation (EU) 2017/746, plus any expenses for external expert assessments	3.296
X.3	Determination procedure pursuant to Article 5a MPG as amended by Federal Law Gazette I No. 46/2021 or Article 10 MPG 2021 as amended regarding the differentiation of a medical device from other products, plus any expenses for external expert assessments	3.296



X.4	Determination procedure pursuant to Article 5a MPG as amended by Federal Law Gazette I No. 46/2021 or Article 10 MPG 2021 as amended regarding the classification of a medical device, plus any expenses for external expert assessments	3.296
XI.	Clinical trials on medicinal products	
XI.1	Clinical trial on medicinal products pursuant to AMG as amended by Federal Law Gazette I No. 23/2020	
XI.1.a	Submission of a phase I, II, or III clinical trial on a medicinal product	3.935
XI.1.b	Submission of a phase IV clinical trial on a medicinal product	1.979
XI.1.c	Submission of a substantial modification of a clinical trial pursuant to Article 37a AMG	655
XI.1.d	Submission of a non-interventional study (NIS) pursuant to Article 2a paragraph 3 AMG or Article 2 paragraph 2 clause 4 of Regulation (EU) 536/2014	790
XI.1.e	Submission of a compassionate-use programme pursuant to Article 8a AMG	
XI.1.e.1	Based on an assessment report of the Committee for Medicinal Products for Human Use (CHMP)	660
XI.1.e.2	Not based on an assessment report of the CHMP	1.979
XI.2	Application for authorisation of a clinical trial on a medicinal product pursuant to Article 5 of Regulation (EU) 536/2014	
XI.2.a	Category A	
XI.2.a.1	With Austria as reporting Member State (national)	
XI.2.a.1.a	Assessment by BASG	1.342
XI.2.a.1.b	Assessment by the competent ethics committee (Part I)	792
XI.2.a.1.c	Assessment by the competent ethics committee (Part II)	792
XI.2.a.2	With Austria as reporting Member State (multinational)	
XI.2.a.2.a	Assessment by BASG	1.953



XI.2.a.2.b	Assessment by the competent ethics committee (Part I)	1.038
XI.2.a.2.c	Assessment by the competent ethics committee (Part II)	792
XI.2.a.3	With Austria as concerned Member State (multinational)	
XI.2.a.3.a	Assessment by BASG	1.342
XI.2.a.3.b	Assessment by the competent ethics committee (Part I)	792
XI.2.a.3.c	Assessment by the competent ethics committee (Part II)	792
XI.2.b	Category B	
XI.2.b.1	With Austria as reporting Member State (national)	
XI.2.b.1.a	Assessment by BASG	2.074
XI.2.b.1.b	Assessment by the competent ethics committee (Part I)	1.464
XI.2.b.1.c	Assessment by the competent ethics committee (Part II)	1.464
XI.2.b.2	With Austria as reporting Member State (multinational)	
XI.2.b.2.a	Assessment by BASG	2.684
XI.2.b.2.b	Assessment by the competent ethics committee (Part I)	1.770
XI.2.b.2.c	Assessment by the competent ethics committee (Part II)	1.464
XI.2.b.3	With Austria as concerned Member State (multinational)	
XI.2.b.3.a	Assessment by BASG	1.342
XI.2.b.3.b	Assessment by the competent ethics committee (Part I)	1.403
XI.2.b.3.c	Assessment by the competent ethics committee (Part II)	1.464
XI.2.c	Category C	
XI.2.c.1	With Austria as reporting Member State (national)	
XI.2.c.1.a	Assessment by BASG	4.515



XI.2.c.1.b	Assessment by the competent ethics committee (Part I)	3.233
XI.2.c.1.c	Assessment by the competent ethics committee (Part II)	3.233
XI.2.c.2	With Austria as reporting Member State (multinational)	
XI.2.c.2.a	Assessment by BASG	5.857
XI.2.c.2.b	Assessment by the competent ethics committee (Part I)	3.965
XI.2.c.2.c	Assessment by the competent ethics committee (Part II)	3.233
XI.2.c.3	With Austria as concerned Member State (multinational)	
XI.2.c.3.a	Assessment by BASG	1.953
XI.2.c.3.b	Assessment by the competent ethics committee (Part I)	3.173
XI.2.c.3.c	Assessment by the competent ethics committee (Part II)	3.233
XI.2.d	Fees for additional expenses in relation to clinical trial authorisations	
XI.2.d.1	For each additional investigational medicinal product not authorised within the EEA, the sum total of fees payable for positions XI.2a-d for services performed by BASG increases by	3.173
XI.2.d.2	For clinical trials consisting of several substudies (multiphase or integrated design), the sum total of fees payable for positions XI.2a-d for services performed by BASG increases by	792
XI.2.d.3	For clinical trials consisting of several substudies (multiphase or integrated design), the sum total of fees payable for positions XI.2a-d for services performed by the ethics committee increases by	1.464
XI.2.d.4	For investigational medicinal products considered advanced therapies pursuant to Article 1 paragraph 6a AMG, the sum total of fees payable for positions XI.2a-d for services performed by the ethics committee increases by	1.464
XI.2.d.5	For each substudy with a separate patient information document, the sum total of fees payable for positions XI.2a-d for services performed by the ethics committee increases by	733
XI.2.d.6	For each additional trial site, the sum total of fees payable for positions XI.2a-d for services performed by the ethics committee increases by	733
XI.2.e	Processing a split submission for authorisation pursuant to Article 11 of Regulation (EU) 536/2014 by BASG	244



XI.3	Application for the authorisation of a substantial modification of a clinical trial pursuant to Chapter III of Regulation (EU) 536/2014	
XI.3.a	Category A	
XI.3.a.1	With Austria as reporting Member State (national)	
XI.3.a.1.a	Assessment by BASG	549
XI.3.a.1.b	Assessment by the competent ethics committee	854
XI.3.a.2	With Austria as reporting Member State (multinational)	
XI.3.a.2.a	Assessment by BASG	672
XI.3.a.2.b	Assessment by the competent ethics committee	854
XI.3.a.3	With Austria as concerned Member State (multinational)	
XI.3.a.3.a	Assessment by BASG	549
XI.3.a.3.b	Assessment by the competent ethics committee	854
XI.3.b	Category B	
XI.3.b.1	With Austria as reporting Member State (national)	
XI.3.b.1.a	Assessment by BASG	549
XI.3.b.1.b	Assessment by the competent ethics committee	854
XI.3.b.2	With Austria as reporting Member State (multinational)	
XI.3.b.2.a	Assessment by BASG	672
XI.3.b.2.b	Assessment by the competent ethics committee	854
XI.3.b.3	With Austria as concerned Member State (multinational)	
XI.3.b.3.a	Assessment by BASG	549
XI.3.b.3.b	Assessment by the competent ethics committee	854



XI.3.c	Category C	
XI.3.c.1	With Austria as reporting Member State (national)	
XI.3.c.1.a	Assessment by BASG	792
XI.3.c.1.b	Assessment by the competent ethics committee	854
XI.3.c.2	With Austria as reporting Member State (multinational)	
XI.3.c.2.a	Assessment by BASG	1.038
XI.3.c.2.b	Assessment by the competent ethics committee	854
XI.3.c.3	With Austria as concerned Member State (multinational)	
XI.3.c.3.a	Assessment by BASG	792
XI.3.c.3.b	Assessment by the competent ethics committee	854
XI.3.d	Fees for additional expenses in relation to an application for authorisation of a clinical trial modification	
XI.3.d.1	Each addition of a new investigational medicinal product not authorised within the EEA increases the sum total of fees payable for above positions for services performed by BASG by	3.173
XI.3.d.2	The addition of a trial site in the course of another substantial modification of a clinical trial increases the sum total of fees payable for above positions for services performed by the ethics committee by	733
XI.3.e	Processing a split submission for authorisation of a modification pursuant to Article 20 of Regulation (EU) 536/2014 by BASG	244
XI.4	Notification of BASG of clinical trial changes not requiring authorisation	
XI.4.a	With Austria as reporting Member State (national and multinational)	427
XI.5	Assessment of the annual safety report pursuant to Article 43 of Regulation (EU) 536/2014 by BASG	
XI.5.a	Category A	
XI.5.a.1	With Austria as reporting Member State (national)	306
XI.5.a.2	With Austria as reporting Member State (multinational)	549



XI.5.a.3	With Austria as concerned Member State (multinational)	366
XI.5.b	Category B	
XI.5.b.1	With Austria as reporting Member State (national)	306
XI.5.b.2	With Austria as reporting Member State (multinational)	549
XI.5.b.3	With Austria as concerned Member State (multinational)	366
XI.5.c	Category C	
XI.5.c.1	With Austria as reporting Member State (national)	549
XI.5.c.2	With Austria as reporting Member State (multinational)	1.342
XI.5.c.3	With Austria as concerned Member State (multinational)	366
XI.6	Corrective measures taken by BASG pursuant to Article 77 of Regulation (EU) 536/2014 plus expenses for external expert reports	1.038
XI.7	Application for transition of a clinical trial authorised pursuant to Directive 2001/20/EC to Regulation (EU) 536/2014	
XI.7.a	Assessment by BASG	549
XI.7.b	Assessment by the competent ethics committee	854
XI.8	Application for authorisation of a clinical trial on a veterinary medicinal product pursuant to Article 10 TAMG in conjunction with Article 9 of Regulation (EU) 2019/6	
XI.8.a	Application for authorisation of a clinical trial on a veterinary medicinal product without specifying waiting periods	2.362
XI.8.b	Application for authorisation of a clinical trial on a veterinary medicinal product, with waiting periods specified	3.764
XII.	Clinical investigation of medical devices, performance evaluation of IVDs, and performance studies with IVDs	
XII.1	Clinical investigation of medical devices pursuant to Directive 90/385/EEC or 93/42/EEC and performance evaluation for in vitro diagnostics pursuant to Directive 98/79/EC	
XII.1.a	Notification of a substantial modification of a clinical investigation or performance evaluation pursuant to Article 40a MPG as amended by	649



	Federal Law Gazette I No. 46/2021	
XII.2	Clinical investigation of medical devices pursuant to Regulation (EU) 2017/745 or Article 13 paragraph 3 MPG 2021 as amended	
XII.2.a	Application for authorisation of a clinical investigation of a medical device pursuant to Article 70 paragraph 7b of Regulation (EU) 2017/745 or Article 13 paragraph 3 MPG 2021 as amended, where at least one of the medical devices used does not bear a valid CE marking or has been modified	8.054
XII.2.b	Application for authorisation of a clinical investigation of a medical device pursuant to Article 70 paragraph 7b of Regulation (EU) 2017/745 or Article 13 paragraph 3 MPG 2021 as amended, where all medical devices used bear a valid CE marking and have not been modified	2.928
XII.2.c	Notification of a clinical investigation pursuant to Article 70 paragraph 7a of Regulation (EU) 2017/745, where at least one of the medical devices used does not bear a valid CE marking or has been modified	5.125
XII.2.d	Notification of a clinical investigation pursuant to Article 70 paragraph 7a of Regulation (EU) 2017/745, where all medical devices used bear a valid CE marking and have not been modified	2.197
XII.2.e	Notification of a clinical investigation pursuant to Article 74 paragraph 1 of Regulation (EU) 2017/745 (post-market clinical follow-up [PMCF] investigation)	915
XII.2.f	Notification of a clinical investigation pursuant to Article 13 paragraph 3 MPG 2021 as amended	915
XII.2.g	Notification of a substantial modification pursuant to Article 75 of Regulation (EU) 2017/745 or Article 13 paragraph 3 MPG 2021 as amended that affects the clinical investigation plan, the investigator's brochure, or the investigational medical device	1.342
XII.2.h	Notification of a modification of the clinical investigation plan, the investigator's brochure, or the investigational medical device not covered by Article 75 of Regulation (EU) 2017/745 or Article 13 paragraph 3 MPG 2021 as amended, provided it is not part of a notification in accordance with XII.2.f	915
XII.3	Performance studies with IVD pursuant to Regulation (EU) 2017/746	
XII.3.a	Application for authorisation of a performance study of an IVD pursuant to Article 66 paragraph 7b of Regulation (EU) 2017/746, where at least one of the IVDs used does not bear a valid CE marking or has been modified	3.892
XII.3.b	Application for authorisation of a performance study of an IVD pursuant to Article 66 paragraph 7b of Regulation (EU) 2017/746, where all of the IVDs used bear a valid CE marking and have not been modified	2.197



XII.3.c	Notification of the performance study of an IVD pursuant to Article 66 paragraph 7a of Regulation (EU) 2017/746, where at least one of the IVDs used does not bear a valid CE marking or has been modified	2.197
XII.3.d	Notification of the performance study of an IVD pursuant to Article 66 paragraph 7a of Regulation (EU) 2017/746, where all of the IVDs used bear a valid CE marking and have not been modified	915
XII.3.e	Notification of a performance study pursuant to Article 70 paragraph 1 of Regulation (EU) 2017/746 ("post-market performance follow-up [PMPF] study")	915
XII.3.f	Notification of a performance study involving a companion diagnostic pursuant to Article 58 paragraph 2 of Regulation (EU) 2017/746, where only left-over samples are used	915
XII.3.g	Notification of a substantial modification pursuant to Article 71 of Regulation (EU) 2017/746 that affects the performance study plan, the investigator's brochure, or the investigational IVD	649
XII.3.h	Notification of a modification of the performance study plan, the investigator's brochure, or the investigational IVD not covered by Article 71 of Regulation (EU) 2017/746, provided it is not part of a notification in accordance with XII.3.g	414
XIII.	Free sales certificates (e.g., for export to non-EEA countries) for medical devices or IVDs	
XIII.1	Application for a (newly issued) free sales certificate for one country for medical devices and/or IVDs, by number of items applied for	
XIII.1.a	Application for a free sales certificate for one country for single devices, accessories, and/or components (1 to 10 items)	636
XIII.1.b	Application for a free sales certificate for one country for single devices, accessories, and/or components (11 to 50 items)	824
XIII.1.c	Application for a free sales certificate for one country for single devices, accessories, and/or components (51 to 250 items)	1.016
XIII.1.d	Application for a free sales certificate for one country for single devices, accessories, and/or components (250 or more items)	1.208
XIII.2	Application for issuance of a confirmation for one country for products that are intended exclusively for export to a non-EEA country and that will not be marketed by the manufacturer as medical device	
XIII.2.a	Request for confirmation for one country for 1 to 10 items	636
XIII.2.b	Request for confirmation for one state for 11 to 50 items	824



XIII.2.c	Request for confirmation for one state for 51 to 250 items	1.016
XIII.2.d	Request for confirmation for one state for 251 or more items	1.208
XIII.3	Each additional identical free sales certificate in accordance with XIII.1 for one country when applied for simultaneously and each additional request for an identical confirmation in accordance with XIII.2 for one country when applied for simultaneously	127
XIV.	Official certifications	
XIV.1	Per copy	329
XIV.2	Each additional copy, when more than one identical official certifications are issued simultaneously	66
XV.	Ordinance on Safeguarding the Supply of Medicinal Products	
XV.1	Notification pursuant to Article 1 paragraph 1 and procedure pursuant to Article 3 paragraph 1 of the Ordinance on Safeguarding the Supply of Medicinal Products	819
XVI.	Notified bodies	
XVI.1	Application by conformity assessment bodies for designation pursuant to Article 38 of Regulation (EU) 2017/745 or Article 34 of Regulation (EU) 2017/746	414.869
XVI.2	Monitoring and reassessment of a notified body pursuant to Article 44 of Regulation (EU) 2017/745 or Article 40 of Regulation (EU) 2017/746 based on the amount of time spent as specified in Article 8 paragraph 2 of this Ordinance, plus any expenses for external expert assessments	
XVI.3	Changes to designations and notifications pursuant to Article 46 of Regulation (EU) 2017/745 or Article 42 of Regulation (EU) 2017/746 based on the amount of time spent in accordance with Article 8 paragraph 2 of this Ordinance, plus any expenses for external expert assessments	